Clinical Trials
4 trialsNCT06050122 2025-10-14
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Sol-Gel Technologies, Ltd.
Phase 3 Active not recruiting
NCT04308395 2024-09-24
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Sol-Gel Technologies, Ltd.
Phase 3 Terminated
NCT03703310 2024-07-03
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Sol-Gel Technologies, Ltd.
Phase 3 Completed
NCT00049959 2011-03-16
Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.
QLT Inc.
Phase 3 Terminated